Cost-effectiveness of nonavalent HPV vaccine in Norway considering current empirical data and validation

Prev Med. 2021 Sep:150:106688. doi: 10.1016/j.ypmed.2021.106688. Epub 2021 Jul 21.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Female
  • Humans
  • Norway
  • Papillomavirus Infections* / prevention & control
  • Papillomavirus Vaccines*
  • Uterine Cervical Neoplasms* / prevention & control
  • Vaccines, Combined

Substances

  • Papillomavirus Vaccines
  • Vaccines, Combined